Context Therapeutics (NASDAQ: CNTX) — Perfil da empresa, notícias e dados financeiros
Context Therapeutics is a biotechnology company focused on hormone-driven cancers, developing treatments for breast and ovarian cancers.

Context Therapeutics
Context Therapeutics (NASDAQ:CNTX) is a biotechnology company focused on advancing treatments for hormone-driven cancers, with a deep commitment to innovation in this critical area of oncology. The company's operations center around developing small molecules and biologics that could potentially transform the therapeutic landscape for patients suffering from breast, ovarian, and other types of hormone-receptor-positive cancers. Among its leading projects is the development of novel therapies that aim to disrupt the cancer growth pathways, providing more effective and less toxic treatment options. The overarching objective of Context Therapeutics is to deliver breakthrough treatments that can significantly improve patient outcomes and quality of life, demonstrating their commitment to addressing the unmet needs in cancer care.
Resumo
Operações
Produtos e/ou serviços de Context Therapeutics
- Onapristone extended release tablets, designed to block the progesterone receptor for treating progesterone-driven cancers.
- Collaborations in clinical trials, combining their leading drug with other therapies for enhanced cancer treatment.
- Development of novel therapies targeting hormone-driven cancers, aiming to provide new options for patients.
- Research into the biology of progesterone receptor (PR) in cancer, supporting the foundation of their therapeutic development.
- Preclinical programs focused on discovering additional candidates that target hormone receptors to expand their pipeline.
- Partnerships with academic and research institutions to leverage cutting-edge science in hormone-driven cancers.
equipe executiva do Context Therapeutics
- Martin A. LehrCo-Founder, President, CEO & Director
- Jennifer Minai-AzaryCFO & Treasurer
- Alex C. LevitChief Legal Officer & Corporate Secretary
- Christopher BeckSenior Vice President of Operations
- Jeffrey LiebmanAssociate Director of Accounting
- Jennifer DashnauSenior Vice President of Technical Operations
- Karen ChaginChief Medical Officer
Últimas notícias sobre a Context Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Context Therapeutics, em USD.
- Cap. de mercado
- 19,4 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -39,7 mi | -36,1 mi | |
| 0 | -29,9 mi | -26,7 mi | |
| 0 | -25,1 mi | -24 mi | |
| 0 | -15,4 mi | -14,8 mi |